IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 4416 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (46 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed3475    
    Printed42    
    Emailed0    
    PDF Downloaded249    
    Comments [Add]    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2008  |  Volume : 74  |  Issue : 4  |  Page : 396-397

Hydroxychloroquine versus chloroquine in polymorphic light eruption


Department of Dermatology and STD, Sri Devaraj Urs Medical College, Tamaka, Kolar-563 101, India

Correspondence Address:
Gurcharan Singh
108, A, Jal Vayu Vihar, Kamanahalli, Bangalore-560 043
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.42920

Rights and Permissions



How to cite this article:
Singh G, Archana G. Hydroxychloroquine versus chloroquine in polymorphic light eruption. Indian J Dermatol Venereol Leprol 2008;74:396-7

How to cite this URL:
Singh G, Archana G. Hydroxychloroquine versus chloroquine in polymorphic light eruption. Indian J Dermatol Venereol Leprol [serial online] 2008 [cited 2019 May 27];74:396-7. Available from: http://www.ijdvl.com/text.asp?2008/74/4/396/42920


Sir,

We read the article titled "Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: A randomized, double-blind, multicentric study" with great interest. However, we wish to point out the following incongruities observed in this study.

The conclusion drawn about superior efficacy and tolerability of hydroxychloroquine over chloroquine is not corroborated by the findings of the study, where only a marginal difference was observed in the efficacy of the two drugs, and in fact, chloroquine fared better in the side effect profile. [1]

Negative serological tests for light eruption (LE) are pertinent and desirable for the diagnosis of polymorphic light eruption (PLE) patients as PLE and LE may often coexist and PLE precedes LE in a subset of the patients. [2],[3]

The lack of ocular toxicity observed in the hydroxychloroquine treatment group after a short course of therapy is understandable as the same is expected after long-term use only. The important risk factors for ocular toxicity associated with hydroxychloroquine therapy are: excessive daily dosage, increasing cumulative dosage, the duration of treatment and the patient's age as well as coexistent renal or liver disease and concomitant retinal disease. [4],[5]

 
  References Top

1.Pareek A, Khopkar U, Sacchidanand S, Chandurkar N, Naik GS. Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: A randomized, double-blind, multicentric study. Indian J Dermatol Venereol Leprol 2008;74:18-22.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Nyberg F, Hasan T, Puska P, Stephansson E, Hδkkinen M, Ranki A, et al . Occurrence of polymorphous light eruption in lupus erythematosus. Br J Dermatol 1997;136:217-21.  Back to cited text no. 2    
3.Murphy GM, Hawk JL.The prevalence of antinuclear antibodies in patients with apparent polymorphic light eruption. Br J Dermatol 1991;125:448-51.  Back to cited text no. 3  [PUBMED]  
4.Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006;12:294-304.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Jones. SK Ocular toxicity and hydroxychloroquine: Guidelines for screening. Br J Dermatol 1999;140:3-7.  Back to cited text no. 5    




 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow